Trial Profile
A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2012
Price :
$35
*
At a glance
- Drugs AZD 2066 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- 31 Aug 2012 Results presented at the 14th World Congress on Pain.
- 28 Aug 2012 Primary endpoint 'Pain-intensity' has not been met, based on results presented at 14th World Congress on Pain.
- 28 Aug 2012 Primary endpoint 'Numerical-Rating-Scale' has not been met, based on results presented at 14th World Congress on Pain